We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Blood Test Differentiates Severe COVID-19 from Preeclampsia in Pregnant Women

By LabMedica International staff writers
Posted on 27 Apr 2022

Preeclampsia is an inflammatory condition that appears during pregnancy and whose cause is still unknown. More...

This condition is characterized by high blood pressure combined with organ dysfunctions, such as renal and liver failure. Should preeclampsia not be early diagnosed, it can lead to serious complications for the mother and the baby. Induced delivery and placenta removal are currently the only solution for this condition. Pregnant women who may have preeclampsia may also be tested positive on COVID-19. In those cases, there may be doubts whether they suffer from preeclampsia and asymptomatic COVID-19 or only have COVID-19 with no preeclampsia, as both pathologies present similar clinical signs. Now, a new study has identified indicators which enable differentiating between both pathologies, thus paving the way for a more accurate diagnosis for both diseases and a better risk assessment.

In the new study, researchers at the Josep Carreras Leukemia Research Institute (IJC, Barcelona, Spain) questioned the extent to which preeclampsia and COVID-19 share biological characteristics. They assessed indicators of endothelial dysfunction, blood clotting, angiogenesis and immune function from blood of pregnant women with preeclampsia or COVID-19 and compared them with of healthy pregnant women’s. The research team were successfully able to differentiate preeclampsia from severe COVID-19, thanks to the strong and reproducible differences in the panel of indicators, being angiogenesis (sFlt-1, Ang2 and P1GF), blood clotting (antigen vWF) and endothelial damage (VCAM-1 and sTNFRI) the most patent.

The study also shows that there are shared elements between both pathologies such as the activation of the complement system, an important part of the immune system, even if the alterations caused by COVID-19 are less significant than the ones caused by preeclampsia. These outcomes are a further step in preeclampsia characterization, a little-known pregnancy-related disease but main responsible for maternal and perinatal mortality in the world and premature births. These results are also medically relevant, as they offer diagnostic tools which allow distinguishing preeclampsia from COVID-19 and helping in their clinical management and treatment. The results of the study are considered as the most important review in gynecology.

Related Links:
IJC 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.